PDF herunterladen
CC BY 4.0 · TH Open 2017; 01(02): e139-e145
DOI: 10.1055/s-0037-1613679
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial

Vinai C. Bhagirath
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2   Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
,
John W. Eikelboom
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2   Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
,
Jack Hirsh
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2   Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
,
Michiel Coppens
2   Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
3   Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands
,
Jeffrey Ginsberg
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Thomas Vanassche
2   Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
4   Department of Cardiovascular Sciences, University Hospital, Leuven, Belgium
,
Fei Yuan
2   Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
,
Noel Chan
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2   Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
,
Salim Yusuf
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2   Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
,
Stuart J. Connolly
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2   Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
› Institutsangaben
Weitere Informationen

Publikationsverlauf

13. Oktober 2017

06. November 2017

Publikationsdatum:
12. Dezember 2017 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background In patients with nonvalvular atrial fibrillation (AF), apixaban is given in doses of 5 or 2.5 mg twice daily, according to clinical characteristics. The usual on-treatment range of apixaban drug levels, as determined by apixaban-calibrated anti-factor Xa (anti-Xa) activity, has previously been measured in small cohorts; however, the association between anti-Xa activity and clinical outcomes and the predictors of variability in anti-Xa activity have not been well studied in the AF population.

Methods and Results Anti-Xa activity was measured before taking the morning dose, 3 months after enrollment in the AVERROES study using a calibrated anti-Xa assay (Rotachrom). Patients with two of the following criteria—age >80; weight <60 kg; or creatinine >133 μg/L—received 2.5 mg twice daily (n = 145), while all others received 5 mg twice daily (n = 2,247). A total of 2,392 patients were included, with median follow-up of 1.1 years. Median apixaban anti-Xa activity was 122 ng/mL (interquartile range [IQR]: 63–198 ng/mL) for the entire group; 99 ng/mL (IQR: 60–146 ng/mL) for the 2.5-mg group; and 125 ng/mL (IQR: 64–202 ng/mL) for the 5-mg group (p = 0.003). A relationship was evident between bleeding and anti-Xa activity (p = 0.01), which was driven by minor bleeding. No relationship was evident between major bleeding or stroke/systemic embolism and anti-Xa activity. In those receiving the 5-mg dose, estimated glomerular filtration rate, sex, and age had the strongest association with anti-Xa activity.

Conclusion There is considerable variability in anti-Xa activity among AF patients receiving apixaban. Rates of major bleeding and stroke/systemic embolism were low irrespective of anti-Xa activity.

Clinical Trial Registration ClinicalTrials.gov NCT00496769; https://clinicaltrials.gov/ct2/show/NCT00496769.

Keywords

apixaban - fibrillation - hemorrhage - systemic embolism

Funding

The AVERROES study was sponsored by Bristol-Myers Squibb and Pfizer.


 

  • References

  • 1 Granger CB, Alexander JH, McMurray JJ. , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 2 Connolly SJ, Eikelboom J, Joyner C. , et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (09) 806-817
    CrossrefPubMedGoogle Scholar
  • 3 Halvorsen S, Atar D, Yang H. , et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35 (28) 1864-1872
    CrossrefPubMedGoogle Scholar
  • 4 Ng KH, Shestakovska O, Connolly SJ. , et al. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing 2016; 45 (01) 77-83
    CrossrefPubMedGoogle Scholar
  • 5 Hohnloser SH, Hijazi Z, Thomas L. , et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33 (22) 2821-2830
    CrossrefPubMedGoogle Scholar
  • 6 Easton JD, Lopes RD, Bahit MC. , et al; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11 (06) 503-511
    CrossrefPubMedGoogle Scholar
  • 7 Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285 (22) 2864-2870
    CrossrefPubMedGoogle Scholar
  • 8 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 9 Levey AS, Stevens LA, Schmid CH. , et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150 (09) 604-612
    CrossrefPubMedGoogle Scholar
  • 10 Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104 (06) 1263-1271
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 11 Kowalsk K, Nielsen J, Roy A. , et al. Apixaban exposure and anti-Xa activity in nonvalvular atrial fibrillation patients: an application of population PK/PD analysis. J Pharmacokinet Pharmacodyn 2014; 41: S7-S101 . Abstract M-027
    CrossrefPubMedGoogle Scholar
  • 12 Osanai H, Ajioka M, Masutomi T. , et al. Measurement of anti-factor Xa activity in patients on apixaban for non-valvular atrial fibrillation. Circ J 2015; 79 (12) 2584-2590
    CrossrefPubMedGoogle Scholar
  • 13 Testa S, Tripodi A, Legnani C. , et al; START-Laboratory Register. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res 2016; 137: 178-183
    CrossrefPubMedGoogle Scholar
  • 14 Reilly PA, Lehr T, Haertter S. , et al; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63 (04) 321-328
    CrossrefPubMedGoogle Scholar
  • 15 Ruff CT, Giugliano RP, Braunwald E. , et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; 385 (9984): 2288-2295
    CrossrefPubMedGoogle Scholar
  • 16 Hanna MS, Mohan P, Knabb R, Gupta E, Frost C, Lawrence JH. Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation. Ann N Y Acad Sci 2014; 1329: 93-106
    CrossrefPubMedGoogle Scholar
  • 17 Steinberg BA, Shrader P, Thomas L. , et al; ORBIT-AF Investigators and Patients. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol 2016; 68 (24) 2597-2604
    CrossrefPubMedGoogle Scholar